Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kinnaird, T.; Johnson, T.; Anderson, R.; Gallagher, S.; Sirker, A.; Ludman, P.; de Belder, M.; Copt, S.; Oldroyd, K.; Banning, A.; et al. Intravascular Imaging and 12-Month Mortality After Unprotected Left Main Stem PCI: An Analysis From the British Cardiovascular Intervention Society Database. JACC. Cardiovasc. Interv. 2020, 13, 346–357. [Google Scholar] [CrossRef]
- Stone, G.W.; Sabik, J.F.; Serruys, P.W.; Simonton, C.A.; Généreux, P.; Puskas, J.; Kandzari, D.E.; Morice, M.-C.; Lembo, N.; Brown, W.M.; et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N. Engl. J. Med. 2016, 375, 2223–2235. [Google Scholar] [CrossRef]
- Brener, S.J.; Leon, M.B.; Serruys, P.W.; Smits, P.C.; von Birgelen, C.; Mehran, R.; Kirtane, A.J.; Witzenbichler, B.; Rinaldi, M.J.; Metzger, D.C.; et al. Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention. EuroIntervention 2019, 15, e551–e557. [Google Scholar] [CrossRef] [Green Version]
- Généreux, P.; Rahyab, A.S. Predicting the future for left main revascularisation. Choosing the right fortune teller. EuroIntervention 2020, 16, 16–17. [Google Scholar] [CrossRef]
- Bajraktari, G.; Zhubi-Bakija, F.; Ndrepepa, G.; Alfonso, F.; Elezi, S.; Rexhaj, Z.; Bytyçi, I.; Bajraktari, A.; Poniku, A.; Henein, M.Y. Long-Term Outcomes of Patients with Unprotected Left Main Coronary Artery Disease Treated with Percutaneous Angioplasty versus Bypass Grafting: A Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2020, 9, 2231. [Google Scholar] [CrossRef]
- Garg, A.; Rout, A.; Raheja, H.; Hakeem, H.; Sharma, S. Long-term follow-up of percutaneous coronary intervention versus coronary artery bypass grafting in left main coronary artery disease: A systematic review and meta-analysis. Catheter. Cardiovasc. Interv. 2021, 98, 427–433. [Google Scholar] [CrossRef]
- Head, S.J.; Holmes, D.R.; Mack, M.J.; Serruys, P.W.; Mohr, F.W.; Morice, M.C.; Colombo, A.; Kappetein, A.P.; SYNTAX Investigators. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. JACC. Cardiovasc. Interv. 2012, 5, 618–625. [Google Scholar] [CrossRef] [Green Version]
- Ramadan, R.; Boden, W.E.; Kinlay, S. Management of Left Main Coronary Artery Disease. J. Am. Heart Assoc. 2018, 7. [Google Scholar] [CrossRef]
- Lawton, J.S.; Tamis-Holland, J.E.; Bangalore, S.; Bates, E.R.; Beckie, T.M.; Bischoff, J.M.; Bittl, J.A.; Cohen, M.G.; DiMaio, J.M.; Don, C.W.; et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022, 145, 4–17. [Google Scholar] [CrossRef]
- Neumann, F.-J.; Sousa-Uva, M.; Ahlsson, A.; Alfonso, F.; Banning, A.P.; Benedetto, U.; Byrne, R.A.; Collet, J.-P.; Falk, V.; Head, S.J.; et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2019, 40, 87–165. [Google Scholar] [CrossRef] [Green Version]
- McKavanagh, P.; Zawadowski, G.; Ahmed, N.; Kutryk, M. The evolution of coronary stents. Expert Rev. Cardiovasc. Ther. 2018, 16, 219–228. [Google Scholar] [CrossRef]
- Joo, H.J.; Jeong, H.S.; Jang, D.H.; Kook, H.; Park, J.H.; Hong, S.J.; Yu, C.W.; Lim, D.-S. Comparison between drug-eluting stent implantation and drug-coated balloon angioplasty in patients with left main bifurcation in-stent restenosis lesions. J. Am. Coll. Cardiol. 2019, 73, 1191. [Google Scholar] [CrossRef]
- Sotomi, Y.; Suwannasom, P.; Tenekecioglu, E.; Tateishi, H.; Abdelghani, M.; Serruys, P.W.; Onuma, Y. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use. Expert Rev. Cardiovasc. Ther. 2015, 13, 1127–1145. [Google Scholar] [CrossRef]
- Corballis, N.H.; Wickramarachchi, U.; Vassiliou, V.S.; Eccleshall, S.C. Duration of dual antiplatelet therapy in elective drug-coated balloon angioplasty. Catheter. Cardiovasc. Interv. 2019, 96, 1016–1020. [Google Scholar] [CrossRef]
- Valgimigli, M.; Bueno, H.; Byrne, R.A.; Collet, J.-P.; Costa, F.; Jeppsson, A.; Jüni, P.; Kastrati, A.; Kolh, P.; Mauri, L.; et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur. Heart J. 2018, 39, 213–260. [Google Scholar] [CrossRef]
- Gomez-Lara, J.; Salvatella, N.; Romaguera, R.; Brugaletta, S.; Ñato, M.; Roura, G.; Ferreiro, J.L.; Teruel, L.; Gracida, M.; Sabate, M.; et al. Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: A randomised trial. EuroIntervention 2020, 16, e155–e163. [Google Scholar] [CrossRef]
- Kim, S.; Lee, J.-S.; Kim, Y.-H.; Kim, J.-S.; Lim, S.-Y.; Kim, S.H.; Kim, M.; Ahn, J.-C.; Song, W.-H. Favorable Vasomotor Function after Drug-Coated Balloon-Only Angioplasty of De Novo Native Coronary Artery Lesions. J. Clin. Med. 2022, 11, 299. [Google Scholar] [CrossRef]
- Jeger, R.V.; Farah, A.; Ohlow, M.-A.; Mangner, N.; Möbius-Winkler, S.; Weilenmann, D.; Wöhrle, J.; Stachel, G.; Markovic, S.; Leibundgut, G.; et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet 2020, 396, 1504–1510. [Google Scholar] [CrossRef]
- Merinopoulos, I.; Gunawardena, T.; Wickramarachchi, U.; Richardson, P.; Maart, C.; Sreekumar, S.; Sawh, C.; Wistow, T.; Sarev, T.; Ryding, A.; et al. Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: The SPARTAN DCB study. Clin. Res. Cardiol. 2020, 1–8. [Google Scholar] [CrossRef]
- Rissanen, T.T.; Uskela, S.; Eränen, J.; Mäntylä, P.; Olli, A.; Romppanen, H.; Siljander, A.; Pietilä, M.; Minkkinen, M.J.; Tervo, J.; et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): A single-blind, randomised, non-inferiority trial. Lancet 2019, 394, 230–239. [Google Scholar] [CrossRef]
- Serruys, P.W.; Kogame, N.; Katagiri, Y.; Modolo, R.; Buszman, P.E.; Íñiguez-Romo, A.; Goicolea, J.; Hildick-Smith, D.; Ochala, A.; Dudek, D.; et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: Two-year follow-up of the SYNTAX II study. EuroIntervention 2019, 15, e244–e252. [Google Scholar] [CrossRef] [Green Version]
- Gunawardena, T.; Merinopoulos, I.; Wickramarachchi, U.; Vassiliou, V.; Eccleshall, S. Endothelial Dysfunction and Coronary Vasoreactivity—A Review of the History, Physiology, Diagnostic Techniques, and Clinical Relevance. Curr. Cardiol. Rev. 2021, 17, 85–100. [Google Scholar] [CrossRef]
- Sabaté, M.; Alfonso, F.; Cequier, A.; Romaní, S.; Bordes, P.; Serra, A.; Iñiguez, A.; Salinas, P.; García Del Blanco, B.; Goicolea, J.; et al. Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial. Circulation 2019, 140, 1904–1916. [Google Scholar] [CrossRef]
- Penwala, T.I.; Navaratnam, R.; Omar, A.F.; Ng, Y.P. TCTAP C-061 Drug-coated Balloon Usage in Left Main Bifurcation Lesion. J. Am. Coll. Cardiol. 2019, 73, S131. [Google Scholar] [CrossRef]
- Kinnaird, T.; Gallagher, S.; Anderson, R.; Sharp, A.; Farooq, V.; Ludman, P.; Copt, S.; Curzen, N.; Banning, A.; Mamas, M. Are Higher Operator Volumes for Unprotected Left Main Stem Percutaneous Coronary Intervention Associated With Improved Patient Outcomes?: A Survival Analysis of 6724 Procedures From the British Cardiovascular Intervention Society National Database. Circ. Cardiovasc. Interv. 2020, 13, e008782. [Google Scholar] [CrossRef]
- Ludwig, J.; Mohamed, M.; Mamas, M.A. Left main bifurcation lesions: Medina reclassification revisited-as easy as ABC. Catheter. Cardiovasc. Interv. 2021, 97, 186–187. [Google Scholar] [CrossRef]
- Jeger, R.V.; Eccleshall, S.; Wan Ahmad, W.A.; Ge, J.; Poerner, T.C.; Shin, E.-S.; Alfonso, F.; Latib, A.; Ong, P.J.; Rissanen, T.T.; et al. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc. Interv. 2020, 13, 1391–1402. [Google Scholar] [CrossRef]
- Garcia-Garcia, H.M.; McFadden, E.P.; Farb, A.; Mehran, R.; Stone, G.W.; Spertus, J.; Onuma, Y.; Morel, M.; van Es, G.-A.; Zuckerman, B.; et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation 2018, 137, 2635–2650. [Google Scholar] [CrossRef]
- Sabatine, M.S.; Bergmark, B.A.; Murphy, S.A.; O’Gara, P.T.; Smith, P.K.; Serruys, P.W.; Kappetein, A.P.; Park, S.-J.; Park, D.-W.; Christiansen, E.H.; et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: An individual patient data meta-analysis. Lancet 2021, 398, 2247–2257. [Google Scholar] [CrossRef]
- Kim, T.-H.; Chung, J.-H.; Shin, E.-S. A case of drug-coated balloon treatment for three-vessel stenosis with left main bifurcation lesion. Cardiol. J. 2020, 27, 85–86. [Google Scholar] [CrossRef] [Green Version]
- Shetty, R.; Ganiga Sanjeeva, N.C.; Agarwal, S.; Doshi, M.; Sojitra, P. Unprotected distal left main bifurcation drug eluting stent restenosis: First successful experience with simultaneous kissing balloon dilatation using sirolimus coated balloon. Cardiovasc. Diagn. Ther. 2015, 5, 484–487. [Google Scholar] [CrossRef]
- Yuan, S.L.; Jun, E.J.; Kim, M.H.; Garg, S.; Shin, E.-S. A left main disease repeatedly treated with drug-coated balloon in a patient with poor adherence to medications. Cardiol. J. 2020, 27, 445–446. [Google Scholar] [CrossRef]
- Kim, D.-W.; Om, S.Y.; Park, M.-W.; Park, H.W.; Lee, P.H.; Kang, D.-Y.; Ahn, J.-M.; Lee, C.W.; Park, S.-W.; Park, S.-J.; et al. Comparative effectiveness analysis of percutaneous coronary intervention versus coronary artery bypass grafting in patients with chronic kidney disease and unprotected left main coronary artery disease. EuroIntervention 2020, 16, 27–35. [Google Scholar] [CrossRef]
- Hammad, T.A.; Parikh, M.; Tashtish, N.; Lowry, C.M.; Gorbey, D.; Forouzandeh, F.; Filby, S.J.; Wolf, W.M.; Costa, M.A.; Simon, D.I.; et al. Impact of COVID-19 pandemic on ST-elevation myocardial infarction in a non-COVID-19 epicenter. Catheter. Cardiovasc. Interv. 2021, 97, 208–214. [Google Scholar] [CrossRef]
- Thiele, H.; Akin, I.; Sandri, M.; Fuernau, G.; de Waha, S.; Meyer-Saraei, R.; Nordbeck, P.; Geisler, T.; Landmesser, U.; Skurk, C.; et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N. Engl. J. Med. 2017, 377, 2419–2432. [Google Scholar] [CrossRef] [Green Version]
- Pappalardo, A.; Mamas, M.A.; Imola, F.; Ramazzotti, V.; Manzoli, A.; Prati, F.; El-Omar, M. Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. JACC. Cardiovasc. Interv. 2011, 4, 618–626. [Google Scholar] [CrossRef]
- Liosis, S.; Hochadel, M.; Darius, H.; Behrens, S.; Mudra, H.; Lauer, B.; Elsässer, A.; Gitt, A.K.; Zahn, R.; Zeymer, U.; et al. Effect of renal insufficiency and diabetes mellitus on in-hospital mortality after acute coronary syndromes treated with primary PCI. Results from the ALKK PCI Registry. Int. J. Cardiol. 2019, 292, 43–49. [Google Scholar] [CrossRef]
- Bittl, J.A. Percutaneous Coronary Interventions in the Diabetic Patient. Circ. Cardiovasc. Interv. 2015, 8, e001944. [Google Scholar] [CrossRef] [Green Version]
- Mihajlovic, M.; Marinkovic, M.; Kozieł, M.; Mujovic, N.; Lip, G.Y.H.; Potpara, T.S. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention. Kardiol. Pol. 2020, 78, 512–519. [Google Scholar] [CrossRef]
- Mäkikallio, T.; Holm, N.R.; Lindsay, M.; Spence, M.S.; Erglis, A.; Menown, I.B.A.; Trovik, T.; Eskola, M.; Romppanen, H.; Kellerth, T.; et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): A prospective, randomised, open-label, non-inferiority trial. Lancet 2016, 388, 2743–2752. [Google Scholar] [CrossRef] [Green Version]
- Ludman, P. British Cardiovascular Intervention Society Audit 2019–2020; BCIS: Lutterworth, UK, 2020. [Google Scholar]
- Ahn, J.-M.; Lee, P.H.; Park, S.-J. Practical based approach to left main bifurcation stenting. BMC Cardiovasc. Disord. 2016, 16, 49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Milojevic, M.; Serruys, P.W.; Sabik, J.F.; Kandzari, D.E.; Schampaert, E.; van Boven, A.J.; Horkay, F.; Ungi, I.; Mansour, S.; Banning, A.P.; et al. Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. J. Am. Coll. Cardiol. 2019, 73, 1616–1628. [Google Scholar] [CrossRef] [PubMed]
- Pan, L.; Lu, W.; Han, Z.; Pan, S.; Wang, X.; Shan, Y.; Peng, M.; Qin, X.; Sun, G.; Zhang, P.; et al. Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis. Front. Cardiovasc. Med. 2022, 9, 1028007. [Google Scholar] [CrossRef] [PubMed]
- Merinopoulos, I.; Wickramarachchi, U.; Wardley, J.; Khanna, V.; Gunawardena, T.; Maart, C.; Vassiliou, V.S.; Eccleshall, S.C. Day case discharge of patients treated with drug coated balloon only angioplasty for de novo coronary artery disease: A single center experience. Catheter. Cardiovasc. Interv. 2020, 95, 105–108. [Google Scholar] [CrossRef]
- Gunawardena, T.; Corballis, N.; Merinopoulos, I.; Tsampasian, V.; Reinhold, J.; Eccleshall, S.; Vassiliou, V.S. Acute Vessel Closure or Major Adverse Cardiac Events of Drug-Coated Balloons and Stents: A Systematic Review and Meta-Analysis. BioMed 2022, 2, 442–451. [Google Scholar] [CrossRef]
- O’Keefe, J.H.; Hartzler, G.O.; Rutherford, B.D.; McConahay, D.R.; Johnson, W.L.; Giorgi, L.V.; Ligon, R.W. Left main coronary angioplasty: Early and late results of 127 acute and elective procedures. Am. J. Cardiol. 1989, 64, 144–147. [Google Scholar] [CrossRef]
- Varnauskas, E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N. Engl. J. Med. 1988, 319, 332–337. [Google Scholar] [CrossRef]
- Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N. Engl. J. Med. 1984, 311, 1333–1339. [CrossRef]
- Caracciolo, E.A.; Davis, K.B.; Sopko, G.; Kaiser, G.C.; Corley, S.D.; Schaff, H.; Taylor, H.A.; Chaitman, B.R. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995, 91, 2335–2344. [Google Scholar] [CrossRef]
Paclitaxel DCB (n = 41) | Second-Generation DES (n = 107) | p-Value | |
---|---|---|---|
Age | Mean 73.8 ± 11.7 | Mean 69.8 ± 11.1 | 0.048 * |
Male | 35 (85.4%) | 82 (76.6%) | 0.25 |
Weight (kg) | 84.39 ± 19.10 | 80.81 ± 14.81 | 0.24 |
Hypercholesterolaemia | 11 (26.8%) | 26 (24.3%) | 0.82 |
Hypertension | 23 (56.1%) | 56 (52.3%) | 0.64 |
PVD | 3 (7.3%) | 5 (4.7%) | 0.52 |
CVA | 4 (9.8%) | 6 (5.6%) | 0.36 |
Prior CABG | 1 (2.4%) | 2 (1.9%) | 0.82 |
Heart Failure | 1 (2.4%) | 3 (2.8%) | 0.91 |
Previous PCI | 8 (19.5%) | 31 (29%) | 0.21 |
Prior MI | 9 (22%) | 26 (24.3%) | 0.70 |
eGFR | Mean 69.88 ± 21.87 | Mean 73.43 ± 23.72 | 0.39 |
Smoking | 24 (64.9%) | 58 (56.3%) | 0.39 |
COPD | 3 (7.3%) | 10 (9.3%) | 0.71 |
Family History of IHD | 4 (9.8%) | 10 (9.3%) | 0.93 |
Atrial Fibrillation | 5 (12.2%) | 4 (3.7) | 0.052 |
Diabetes | 13 (31.7%) | 24 (22.4) | 0.23 |
DAPT 1 month 12 months | 19 (46.3%) 22 (53.7%) | 4 (3.7%) 103 (96.3%) | <0.01 |
GPIIbIIIa use | 14 (34.1%) | 20 (18.7%) | 0.06 |
ACS STEMI NSTEMI | 5 (12.2%) 23 (56.1%) | 10 (9.3%) 47 (43.9%) | 0.37 Ɨ |
ELECTIVE Stable Angina Staged | 10 (24.4%) 3 (7.3%) | 43 (40.2.9) 7 (6.5%) |
Paclitaxel DCB (n = 41) | Second-Generation DES (n = 107) | p-Value | |
---|---|---|---|
Radial access | 35 (85.4%) | 88 (82.2%) | 0.67 |
Vessel diameter (mm) | 3.84 ± 0.26 | 4.33 ± 0.60 | <0.001 * |
Lesion length (mm) | 21.71 ± 7.80 | 24.72 ± 14.32 | 0.20 |
True bifurcation | 30 (73.2%) | 52 (48.6%) | 0.006 * |
Contrast | 144.5 ± 41.3 | 176.5 ± 67.1 | 0.006 * |
Intravascular imaging (OCT or IVUS) | 14 (35.9%) | 82 (76.6%) | <0.001 |
Coronary dissection after DCB
| 4 (9.8%) 16 (39.0%) | N/A | |
Calcium modification | |||
Rotational atherectomy | 1 (2.4%) | 7 (6.5%) | 0.32 |
Shockwave lithotripsy | 0 (0%) | 1 (0.9%) | 0.53 |
Cutting balloon | 1 (2.4%) | 0 (0%) | 0.61 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gunawardena, T.D.; Corballis, N.; Merinopoulos, I.; Wickramarachchi, U.; Reinhold, J.; Maart, C.; Sreekumar, S.; Sawh, C.; Wistow, T.; Sarev, T.; et al. Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study. J. Cardiovasc. Dev. Dis. 2023, 10, 84. https://doi.org/10.3390/jcdd10020084
Gunawardena TD, Corballis N, Merinopoulos I, Wickramarachchi U, Reinhold J, Maart C, Sreekumar S, Sawh C, Wistow T, Sarev T, et al. Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study. Journal of Cardiovascular Development and Disease. 2023; 10(2):84. https://doi.org/10.3390/jcdd10020084
Chicago/Turabian StyleGunawardena, Tharusha D., Natasha Corballis, Ioannis Merinopoulos, Upul Wickramarachchi, Johannes Reinhold, Clint Maart, Sulfi Sreekumar, Chris Sawh, Trevor Wistow, Toomas Sarev, and et al. 2023. "Drug-Coated Balloon vs. Drug-Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN-LMS Study" Journal of Cardiovascular Development and Disease 10, no. 2: 84. https://doi.org/10.3390/jcdd10020084